SCHEMBL5380311

SCHEMBL5380311

CN(C)C(=O)n1cnc(S(=O)(=O)N2CCCCC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.43
GLA P06280 1/20 0.39
KMT2A Q03164 2/20 0.38
MAPT P10636 6/20 0.38
ALDH1A1 P00352 5/20 0.37
USP2 O75604 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
CNR2 P34972 1/20 0.36
POLB P06746 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ATM Q13315 1/20 0.36
TSHR P16473 1/20 0.36
GAA P10253 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11559837 0.86 DPP4 (0.41) DPP4GLAKMT2AMAPTALDH1A1
SCHEMBL11559102 0.86 ALDH1A1 (0.41) DPP4GLAKMT2AMAPTALDH1A1
SCHEMBL11566923 0.85 KMT2A (0.42) DPP4GLAKMT2AMAPTALDH1A1
SCHEMBL11564512 0.85 CNR2 (0.47) DPP4KMT2AMAPTALDH1A1USP2
SCHEMBL11556857 0.85 CNR2 (0.47) DPP4KMT2AMAPTALDH1A1USP2
SCHEMBL11556816 0.85 DPP4 (0.39) DPP4GLAKMT2AMAPTALDH1A1
SCHEMBL11566494 0.83 DPP4 (0.46) DPP4GLAKMT2AMAPTLMNA
SCHEMBL11566272 0.83 TSHR (0.43) DPP4KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL11557253 0.81 TSHR (0.42) DPP4KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL11566288 0.81 DPP4 (0.38) DPP4GLAKMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2004-09-23 US disclosed
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI CO., LTD. (JP) 2003-03-27 US disclosed
EP-1258480-A1 Pharmaceutical use of N-Carbamoylazole derivatives Eisai Co., Ltd. (JP) 2002-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 DPP4 1/4885GLA 1383/4885KMT2A 2591/4885
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 DPP4 1/4885GLA 1383/4885KMT2A 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.